Patents Assigned to SmithKline Beecham p.1.c.
  • Publication number: 20020137773
    Abstract: A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range from >126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitizer, to a mammal in need thereof.
    Type: Application
    Filed: May 24, 2002
    Publication date: September 26, 2002
    Applicant: SmithKline Beecham p.1.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20020132840
    Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of angina.
    Type: Application
    Filed: March 15, 2002
    Publication date: September 19, 2002
    Applicant: SmithKline Beecham p.1.c.
    Inventor: James Hill
  • Publication number: 20020099044
    Abstract: Paediatric aqueous liquid suspension formulations comprising amoxycillin trihydrate and potassium clavulanate in a ratio of from 6:1 to 8:1 are provided for use in a BID dosage regimen for treating bacterial infection.
    Type: Application
    Filed: January 11, 2002
    Publication date: July 25, 2002
    Applicant: SmithKline Beecham p.1.c.
    Inventors: Richard Peregrine Bax, Mike Gale Ramsey
  • Publication number: 20020082200
    Abstract: Inhibitors of matrix metalloproteases such as collagenase are capable of inhibiting the release of human soluble CD23 and are therefore useful in the treatment and prophylaxis of conditions in which an excess of s-CD23 is implicated, such as allergy and autoimmune disease.
    Type: Application
    Filed: January 3, 2002
    Publication date: June 27, 2002
    Applicant: SmithKline Beecham p.1.c.
    Inventors: Gary Christie, Beverly Jane Weston
  • Publication number: 20020081602
    Abstract: A method for the detection of a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, which method comprises: (a) for a compound which mimics the physiological effect of the ob-protein, assessing the effect of the compound upon an ob-protein activated signal transducer and activator of transcription (STAT) DNA response element coupled to a reporter gene; or (b) for a compound which potentiates or inhibits the physiological effect of the ob-protein, assessing the effect of the compound upon the response provided by ob-protein upon an ob-protein activated STAT DNA response element coupled to a reporter gene; wherein, the response element and the reporter being expressed in an ob-protein response cell line, which cell line is selected from the list consisting of: a hypothalamic derived cell line; a pheochromocytoma derived cell line; a haematopoietic derived cell line; a pancreatic derived cell line; a liver derived cell line; a preadipocyte derived cell line; a skeletal muscl
    Type: Application
    Filed: April 26, 2001
    Publication date: June 27, 2002
    Applicant: SmithKline Beecham p.1.c.
    Inventor: Lee James Beeley
  • Patent number: 6365154
    Abstract: Tie2 receptor agonist antibodies, their use in enhancing angiogenesis and other uses are disclosed.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: April 2, 2002
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.1.c.
    Inventors: Stephen D. Holmes, Connie L. Erickson-Miller, James D. Winkler
  • Patent number: 5747315
    Abstract: The invention provides aspS polypeptides and DNA (RNA) encoding aspS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aspS polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: May 5, 1998
    Assignees: SmithKline Beecham Corp., SmithKline Beecham p.1.c.
    Inventor: Elizabeth Jane Lawlor